Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?

Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?

Da: GRACEcast
0 0 8 anni fa
Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.

Seguici su Facebook